Novavax (NASDAQ:NVAX) released its earnings results on Thursday. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.98) by $0.24, RTT News reports. The firm had revenue of $2.51 million during the quarter, compared to the consensus estimate of $4.40 million. During the same quarter in the previous year, the firm earned ($2.40) EPS.
Novavax stock traded up $0.09 during trading hours on Friday, reaching $4.59. The company had a trading volume of 858,200 shares, compared to its average volume of 807,410. The firm has a market cap of $106.69 million, a price-to-earnings ratio of -0.46 and a beta of 1.90. The company has a 50-day moving average price of $4.91 and a 200 day moving average price of $4.94. Novavax has a 12-month low of $4.01 and a 12-month high of $51.60.
In other Novavax news, insider Gregory M. Glenn sold 9,620 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $6.18, for a total value of $59,451.60. Following the sale, the insider now directly owns 123 shares of the company’s stock, valued at $760.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO John Trizzino sold 5,578 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $5.72, for a total value of $31,906.16. Following the completion of the sale, the chief financial officer now directly owns 4,800 shares in the company, valued at $27,456. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,841 shares of company stock worth $117,114. 3.30% of the stock is owned by insiders.
A number of analysts recently weighed in on the company. B. Riley set a $35.00 target price on Novavax and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Cantor Fitzgerald restated a “neutral” rating on shares of Novavax in a research report on Thursday, October 17th. Citigroup dropped their target price on Novavax from $19.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, September 24th. ValuEngine upgraded Novavax from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, HC Wainwright boosted their target price on Novavax from $10.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Three analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Novavax presently has an average rating of “Hold” and a consensus price target of $31.15.
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
See Also: What is a price target?
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.